Want to see ATRA full AI Analyst Report?
ATRA Stock Chart & Stats
$7.90
-$0.27(-3.30%)
At close: 4:00 PM EDT
$7.90
-$0.27(-3.30%)
Day’s Range― - ―
52-Week Range$3.92 - $19.15
Previous CloseN/A
Volume75.24K
Average Volume (3M)80.44K
Market Cap
$75.51M
Enterprise Value$109.81
Total Cash (Recent Filing)$8.36M
Total Debt (Recent Filing)$10.09M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 10, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding9,010,172
10 Day Avg. Volume79,276
30 Day Avg. Volume80,440
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside73.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$2.08M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginA TTM gross margin near 96% reflects strong product/contract economics and suggests that incremental revenue converts efficiently to gross profit. For a development-stage biotech, durable high gross margins improve the long-term scalability of future commercial revenues and support eventual operating leverage.
Strategic Partnership FundingAtara’s collaboration model, exemplified by the Pierre Fabre partnership, delivers upfront, milestone and cost-sharing payments that reduce sole-company funding needs. Structurally this provides non-dilutive or shared-investment financing, access to partner commercialization resources, and de-risks program advancement over the medium term.
Clearer Regulatory Path For Tab-celA constructive Type A meeting for tab-cel that accepts a well-designed single-arm study with historical controls materially clarifies the clinical/regulatory pathway. This structural regulatory guidance increases the program’s approval probability and shortens time-to-decision, improving long-term commercial prospects if met.
Bears Say
Negative Shareholder EquitySustained negative equity indicates the capital structure is impaired and raises solvency concerns. Over months this can constrain access to debt, create higher financing costs, and limit strategic flexibility; it also makes the company more reliant on dilutive equity or partner funding to sustain operations and programs.
Persistent Cash BurnConsistent negative operating and free cash flow of roughly -$25.9M TTM shows the business requires ongoing external funding to progress trials and operations. Over a 2–6 month horizon this increases refinancing risk, can delay development timelines if capital access tightens, and pressures management to secure partnerships or raise capital.
Nasdaq Non-compliance / Delisting RiskA Nasdaq non-compliance notice threatens delisting if market value isn’t restored by the deadline. This structural listing risk can materially reduce liquidity, hinder access to institutional capital, and force strategic changes (transfer to a different market or heightened dilution) that affect funding and investor base over the medium term.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $3.92 and its highest was $19.14 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $75.51M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 8 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on May 12, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -0.32.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 9,010,172 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 6.83%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Currently, no hedge funds are holding shares in ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.67 (73.00% Upside)
$13.67 (73.00% Upside)
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-67.77%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
ATRA Stock 12 Month Forecast
Average Price Target
$13.67
▲(73.00% Upside)
Technical Analysis
Ownership Overview
55.97% Insiders
5.41% Mutual Funds
<0.01% Other Institutional Investors
35.59% Public Companies and
Individual Investors